Glucose-insulin and potassium infusions in septic shock

Chest

Volumn 129, Issue 3, 2006, Pages 800-804

  Hamdulay, Shahir S ^a,c   Khafaji, Ali Al ^b   Montgomery, Hugh ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Antiinflaminatory; Glucose insulin and potassium; Insulin; Myocardium; Sepsis; Shock

Indexed keywords

ACTIVATED PROTEIN C; ADRENALIN; AMIODARONE; AMPHOTERICIN; BICARBONATE; CEFTAZIDIME; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; FLUCONAZOLE; FOSCARNET; GENTAMICIN; GLUCOSE; HYPERTENSIVE AGENT; INSULIN; MAGNESIUM SULFATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORADRENALIN; PIPERACILLIN PLUS TAZOBACTAM; POTASSIUM; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SODIUM; TEICOPLANIN; VASOPRESSIN; VINCRISTINE;

ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; B CELL LYMPHOMA; CANDIDIASIS; CARDIOVERSION; DEATH; DRUG MEGADOSE; DYSPNEA; HEART ATRIUM FIBRILLATION; HEMODYNAMICS; HEMOFILTRATION; HUMAN; HYPOTENSION; HYPOXEMIA; METABOLIC ACIDOSIS; NEUTROPENIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROGNOSIS; RESUSCITATION; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION;

EID: 33645130426     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.3.800     Document Type: Article

References (28)

1. Parrillo JE. Pathogenic mechanisms of septic shock. N Engl J Med 1993; 28:1471-1477
2. Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock. Crit Care Clin 2000; 16:251-287
3. Grocott-Mason RM, Shah AM. Cardiac dysfunction in sepsis: new theories and clinical implications. Intensive Care Med 1998; 24:286-295
4. Krishnagopalan S, Kumar A, Parrillo JE, et al. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 2002; 8:376-388
5. Cunnion RE, Schaer GL, Parker MM, et al. The coronary circulation in human septic shock. Circulation 1988; 73:637-644
6. Dhainaut JF, Huyghebaert MF, Monsallier JF, et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987; 75:533-541
7. Sodi-Palleres D, Testelli M, Fishelder F. Effects of an intravenous infusion of potassium-insulin-glucose on the electrocardiographic signs of myocardial infarction. Am J Cardiol 1962; 9:166-181
8. Apstein CS, Taegtmeyer H. Glucose-insulin-potassium in acute myocardial infarction. Circulation 1997; 96:1074-1077
9. Ramanathan T, Shirota K, Morita S, et al. Glucose-insulin-potassium improves left ventricular mechanics in diabetes. Ann Thorac Surg 2002; 73:582-587
10. Jonassen AK, Aasum E, Riemersma RA, et al. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 2000; 14:615-623
11. Marano L, Bestetti A, Lomuscio A, et al. Effects of infusion of glucose-insulin-potassium on myocardial function after a recent myocardial infarction. Acta Cardiol 2000; 55:9-15
12. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997; 96:1152-1156
13. Diaz R, Paolasso EC, Piegas LS, et al, on behalf of the ECLA Collaborative Group. Metabolic modulation of acute myocardial infarction: the ECLA glucose-insulin-potassium pilot trial. Circulation 1998; 98:2227-2234
14. Pache J, Kastrati A, Mehilli J, et al. A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. Am Heart J 2004; 148:e3
15. Castro PF, Larrain G, Baeza R, et al. Effects of glucose-insulin- potassium solution on myocardial salvage and left ventricular function after primary angioplasty. Crit Care Med 2003; 8:2152-2155
16. van der Horst IC, Zijlstra F, van't Hof AW, et al. Glucose-insulin- potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003; 42:784-791
17. Mehta SR, Yusuf S, Diaz R, Zhu J, et al. Effect of glucose-insulin- potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005; 293:437-446
18. Broomhead CJ, Colvin MP. Glucose, insulin, and the cardiovascular system. Heart 2001; 85:495-496
19. Mauritz W, Schindler I, Zadrobilek E, et al. Glucose-potassium-insulin in hypodynamic septic shock. Anaesthetist 1986; 35:623-627
20. Bronsveld W, van den Bos GC, Thijs LG. Use of glucose-insulin-potassium (GIK) in human septic shock. Crit Care Med 1985; 13:566-570
21. Das UN. Insulin; an endogenous cardioprotector. Curr Opin Crit Care 2003; 9:375-383
22. Gao F, Gao E, Yue T-L, et al. Nitric oxide mediates the antiapoptotic effects of insulin in myocardial ischaemia-reperfusion: the roles of PI3-ldnase, Akt and endothelial nitric oxide synthase phosphorylation. Circulation 2002; 105:1497-1502
23. Maki M, Luotolahti M, Nuutila P, et al. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation 1996; 93:1658-1666
24. McNulty PH. Comparison of local and systemic effects of insulin on myocardial glucose extraction in ischemic heart disease. Am J Physiol (Heart Circ Physiol) 2000; 278:H741-H747
25. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet 1994; 343:155-158
26. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation 1999; 99:578-588
27. Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001; 103:2441-2446
28. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367